For Physicians

A NEW STANDARD OF CARE

Earlier tumor analysis means patients get on the right care plan faster

PreciseBreast®, created to standardize cancer care, eliminates the subjectivity and variability of histologic grade. Specific tumor morphology features are analyzed; results enable earlier assessment of recurrence risk and the likelihood of chemotherapy benefit for shared decision-making.

How PreciseBreast works

Superior risk stratification for earlier shared decision-making

OncoIntelligence™ analyzes a digitized H&E-stained slide and quantifies the morphologic features & clinical factors that impact the risk of disease recurrence.

Digitized H&E-stained breast tissue slide
1

Digital Pathology

PreciseDx first digitizes the same diagnostic H&E-stained slide a pathologist would use for tumor grading.

Illustration of cells analyzed by AI
2

OncoIntelligence™

OncoIntelligence, our AI-platform, analyzes every cell from the digitized image, objectively quantifying morphologic features that reliably predict 10-year risk of distant recurrence.

Pathologists perform Inference Quality Control to optimize the areas of tumor focus.

Illustration of tumor morphology features
3

Algorithm

The proprietary algorithm delivers the quantitative assessment of the morphologic features as an AI-Grade alone or an AI-Grade that includes 4 clinical factors that measure a patient's 10-year individual risk of distant recurrence.

Data waveform illustration
4

PreciseBreast Report

PreciseBreast AI-Grade is the output of the proprietary algorithm.

PreciseBreast / NSABP B-20 Study Facts:

Landmark Level 1B evidence utilizing H&E slides

PreciseBreast / NSABP B-20 Study Objectives:
✓Prognostic Performance for Distant Recurrence
✓PreciseBreast AI-Grade compared to histologic grade
✓Adjuvant chemotherapy benefit
1,607
HR+, node-negative patients
14.2-year
median follow-up from randomized treatment arms
Only
breast cancer study available to compare ET+CT vs. ET alone
30-year-old
H&E slides from NSABP B-20 to perform this study11
Talk to Us →

HR=hormone receptor, H&E=Hematoxylin and Eosin, ET=endocrine therapy, CT=chemotherapy

The Problem

Histologic grade, a leading factor to determine prognosis

The use of subjective grading alone is discouraged.⁴ Levels of inter-observer variation can and should still be improved.⁵ Histologic grade includes pathologist-assigned tubule formation, nuclear pleomorphism, and mitotic count. Grading variability may have influenced adjuvant chemotherapy decisions in 30% of patients.⁶ ⁹

50-60%

of breast tumors are categorized as Grade 2⁷

57-70%

pathologist inter & intra-observer variation⁷ ⁸

54.7%

of Grade 3 tumors are low risk²

25.9%

of Grade 2 tumors are high risk²

74.1%

of Grade 2 tumors are low risk²

1 in 8 women will be diagnosed with breast cancer in their lifetime

LEARN MORE, EARLIER.

More data derived from the existing diagnostic slide

One diagnostic H&E-stained slide is all that is needed for testing. PreciseBreast® identifies 10-year distant recurrence risk with accuracy and reliability.

Precision matters

PreciseBreast® delivers benefits for physicians, patients and payors.

10-year distant recurrence risk

Earlier results lessen anxiety for patients

Lower overall testing and treatment costs

Worldwide access to PreciseBreast®

OUR PROCESS

Superior risk stratification for earlier shared decision‑making

Mass identified & biopsy taken
Biopsy analyzed & breast cancer diagnosed
Surgery: tissue excised
is ordered:
H&E-stained slide, surgical excision
Ship or Digital Transfer to CLIA Lab
Sample PreciseBreast AI-Grade report showing an individual 10-year risk of distant recurrence
Low-Risk
May choose less intervention
High-Risk
May require more intervention
Earlier shared decision-making between physician and patient
Physician - Patient Discussion
Predicts 10-Year DR Risk
Reports CT Benefit
For women newly diagnosed with:
Invasive Ductal Carcinoma³ ¹⁰
HR+, HER2-, Node -Stage I-IIAny Menopausal StatusNo Prior Treatment
HR = hormone receptor, HER2 = human epidermal growth factor receptor 2
CLIA = Clinical Laboratory Improvement Amendments

who we serve

PreciseStories

The results of slow or unavailable gene-expression testing can impact patients and their anxiety levels during a critical time in their lives. These are their stories of how PreciseBreast might have made a difference.

FAQ’s

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare

Is the PreciseBreast® test covered by my health insurance?

A patient’s individual health benefits will determine insurance coverage for the PreciseBreast test. PreciseDx will do all we can to ensure the test is affordable to patients. If you are interested in inquiring about your individual health benefits, please contact your health plan directly. The PreciseBreast billing code is CPT 0220U.

If I have health insurance, will I have any out-of-pocket expense?

There are differences among health insurance programs that determine an individual patient’s covered services, co-insurance, co-pay and deductible. It is difficult to determine what an individual’s out-of-pocket cost might be for the PreciseBreast test until the entire billing and appeals process is complete.

What if my claim is denied by my health insurance plan?

If your health plan denies your claim for any reason, PreciseDx will appeal the claim on your behalf. We will work diligently to get the claim paid through our exhaustive appeal process. You may receive one or more Explanation of Benefits (EOB)(s) during this process. An EOB is NOT A BILL.

If I have gone through the appeals process, but am still unable to pay, what are my options?

Please review the information on our Patient Assistance Program (PAP) to determine whether you qualify for a reduced out-of-pocket cost for the PreciseBreast test. You can also contact our billing department at 855-212-4410.

What is the cost of the test?

The cost of the test will depend on your individual health insurance coverage (for example, in-network, out-of-network, co-insurance, deductible and co-pay). We also offer a Self-Pay program.

Do you have a flexible payment plan?

Yes, we offer several payment plan options, as well as an interest-free payment plan over a period of up to 6 months.

Do you provide financial assistance to cover the cost of the test?

Yes, please contact our billing team to further discuss our Patient Assistance Program (PAP) and eligibility requirements. A copy of our PAP application can be found at precisedx.ai

How do I make a payment?

Please call our billing department at 855-212-4410 to arrange for payments. Diagnostic laboratory tests are also eligible for reimbursement with a Flexible Spending Account (FSA) or a Health Savings Account (HSA). We accept all major credit cards, checks and money orders.

What if my insurance plan sends me a check directly for the cost of the PreciseBreast® test?

1. Endorse the check by signing the back and writing the following under your signature: “Payable to PreciseDx, Inc.” 2. Please mail the check along with any cost-sharing, deductible or co-pay amounts and a copy of the Explanation of Benefits (EOB) to the following address: PreciseDx, Inc. P.O. Box 25532 New York, NY 10087- 5536 Please contact our Billing Team if you have any questions or concerns at 855-212-4410

Let us show you the significance of PreciseBreast®

Contact us today to learn more.

Get in Touch